Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis In Neurology Neuroimmunology & Neuroinflammation

4/30/24 6:32:02 AM ET

$IMUX

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $IMUX alert in real time by email

30 mg and 45 mg Daily Doses of Vidofludimus Calcium Suppressed Development of Gadolinium-Enhancing Lesions by 78% and 74% Compared to Pooled Placebo at 24 Weeks.
Improvements in Serum Neurofilament Light Chain Consistent with Recently Announced Interim Phase 2 CALLIPER Data in Progressive Multiple Sclerosis.
Twin Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis and Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis Remain Underway.

Get the next $IMUX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$IMUX

Date	Price Target	Rating	Analyst
9/9/2024	$5.00	Outperform	Leerink Partners
8/27/2024	$6.00	Buy	B. Riley Securities
10/21/2022	$5.00	Outperform → Mkt Perform	SVB Leerink
9/19/2022	$26.00	Buy	H.C. Wainwright
9/7/2021	$40.00 → $25.00	Buy	HC Wainwright & Co.

More analyst ratings

$IMUX
Leadership Updates

Live Leadership Updates

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec
– Senior Executive and Thought Leader in Brain Health with Nearly Three Decades of Global Pharmaceutical Experience – – Served as Neuroimmunology Franchise Head Responsible for Roche's Blockbuster Launch of Multiple Sclerosis Therapy Ocrevus® – NEW YORK, July 24, 2024 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the appointment of Simona Skerjanec, M.Pharm, MBA, a thought-leader in brain health with decades of experience in drug development and commercialization, to its board of directors, effective July 22, 2024. Over a nea
7/24/24 6:30:00 AM ET
$IMUX
Biotechnology: Pharmaceutical Preparations
Health Care
Immunic Appoints Jason Tardio as Chief Operating Officer and President
– Former Novartis and Biogen Executive Brings Extensive Multiple Sclerosis Drug Commercialization Experience to Immunic – – Werner Gladdines, Current Vice President, Program Management & Clinical Development Operations, Promoted to Chief Development Officer – NEW YORK, July 9, 2024 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that seasoned biopharmaceutical executive, Jason Tardio, will be joining the company as Chief Operating Officer and President, effective July 12, 2024. In the newly created role, Mr. Tardio will lead in
7/9/24 6:30:00 AM ET
$IMUX
Biotechnology: Pharmaceutical Preparations
Health Care
Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D.
– Thought-Leader in Multiple Sclerosis with Decades of Experience in Academic Medicine and the Pharmaceutical Industry – NEW YORK, April 27, 2023 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the appointment of Richard Rudick, M.D., a thought-leader in multiple sclerosis with decades of experience in the clinic, academia and industry, to its board of directors, effective April 26, 2023. The company also announced that Vincent Ossipow, Ph.D., will step down from the Board, effective June 28, 2023. "We are very grateful to have
4/27/23 6:30:00 AM ET
$IMUX
Biotechnology: Pharmaceutical Preparations
Health Care

Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
– 24-Week Data from First Half of Patients Shows Improvements in Biomarker NfL, Consistent Throughout the Overall Progressive Multiple Sclerosis Population as well as All Subtypes – – NfL Effect in Non-Active Subpopulation Reinforces Vidofludimus Calcium's Neuroprotective Potential – – Brain Volume Data of the Full 467 CALLIPER Patient Cohort Expected in April 2025 – – Phase 3 ENSURE Program in Relapsing Multiple Sclerosis Ongoing – – Conference Call and Webcast to be Held Tomorrow, October 10, 2023 at 8:00 am ET – NEW YORK, Oct. 9, 2023 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chr
10/9/23 4:01:00 PM ET
$IMUX
Biotechnology: Pharmaceutical Preparations
Health Care
Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders
– Positive Effects Demonstrated Over Placebo in Four Key Dimensions of Celiac Disease Pathophysiology: Protection of Gut Architecture, Improvement of Patients' Symptoms, Biomarker Response, and Enhancement of Nutrient Absorption – – Corroborates Hypothesized Ability of IMU-856 to Renew Gut Wall and Restore Gut Health – – No Safety or Tolerability Issues Detected – – Conference Call and Webcast to be Held Today, May 4, 2023 at 8:00 am ET – NEW YORK, May 4, 2023 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced positive results fro
5/4/23 6:30:00 AM ET
$IMUX
Biotechnology: Pharmaceutical Preparations
Health Care
Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis
– 50-Week Maintenance Phase Data Shows Dose-Linear Increase in Clinical Remission for Vidofludimus Calcium as Compared to Placebo – – 30 mg Once-Daily Dose of Vidofludimus Calcium Demonstrated Statistically Significant Rates of Clinical Remission (p=0.0358) and Endoscopic Healing (p=0.0259) at Week 50 – – To Focus Resources on High Performing Vidofludimus Calcium and IMU-856 Programs, Immunic Decided to Deprioritize Izumerogant (IMU-935) Program – – Conference Call and Webcast to be Held today, April 5, 2023 at 8:00 am ET – NEW YORK, April 5, 2023 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapi
4/5/23 6:30:00 AM ET
$IMUX
Biotechnology: Pharmaceutical Preparations
Health Care

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology
– Includes Phase 1 Data in Healthy Human Subjects and Phase 1b Data in Celiac Disease Patients – NEW YORK, Nov. 13, 2024 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the data from its phase 1/1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6 (Sirtuin 6), has been published in the peer reviewed journal, The Lancet Gastroenterology & Hepatology. Lead authored by Dr. A. James Daveson, Gastroenterologist, Wesley Research Institute and Coral Sea Clinical Res
11/13/24 6:30:00 AM ET
$IMUX
Biotechnology: Pharmaceutical Preparations
Health Care
Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update
– Positive Interim Analysis of Phase 3 ENSURE Program, Unblinded Independent Data Monitoring Committee Confirmed that Predetermined Futility Criteria Have Not Been Met and Recommended Trials Should Continue as Planned – – Ongoing, Twin Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis and Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis Remain on Track – – Top-Line Data from Phase 2 CALLIPER Trial Expected in April 2025 – – Webcast to be Held Today, November 7, at 8:00 am ET – NEW YORK, Nov. 7, 2024 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoi
11/7/24 6:30:00 AM ET
$IMUX
Biotechnology: Pharmaceutical Preparations
Health Care
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
– Webcast to be Held at 8:00 am ET on November 7, 2024 – NEW YORK, Oct. 31, 2024 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the third quarter ended September 30, 2024, including a corporate update, on Thursday, November 7, 2024, before the opening of the U.S. financial markets. A webcast will follow at 8:00 am ET. To participate in the webcast, please register in advance at: https://imux.zoom.us/webinar/register/WN_v2_K1Ze-QKS34X6c9W9ywg or on the "Events and Presenta
10/31/24 6:30:00 AM ET
$IMUX
Biotechnology: Pharmaceutical Preparations
Health Care

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis In Neurology Neuroimmunology & Neuroinflammation

Chat with this insight

Recent Analyst Ratings for $IMUX

$IMUX SEC Filings

SEC Form 10-Q filed by Immunic Inc.

Immunic Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

Immunic Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

$IMUX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Rudick Richard Alan bought $100,369 worth of shares (87,300 units at $1.15) (SEC Form 4)

Vitt Daniel bought $18,333 worth of shares (14,000 units at $1.31) (SEC Form 4)

$IMUX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Immunic Inc.

Amendment: SEC Form SC 13G/A filed by Immunic Inc.

Amendment: SEC Form SC 13G/A filed by Immunic Inc.

$IMUX Leadership Updates

Live Leadership Updates

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec

Immunic Appoints Jason Tardio as Chief Operating Officer and President

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D.

$IMUX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Rudick Richard Alan bought $100,369 worth of shares (87,300 units at $1.15) (SEC Form 4)

SEC Form 4 filed by Director Skerjanec Simona

SEC Form 3 filed by new insider Skerjanec Simona

$IMUX Financials

Live finance-specific insights

$IMUX Press Releases

Fastest customizable press release news feed in the world

$IMUX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$IMUX Market Insights

Live Market Insights

Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders

Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

Leerink Partners resumed coverage on Immunic with a new price target

B. Riley Securities initiated coverage on Immunic with a new price target

Immunic downgraded by SVB Leerink with a new price target

Piper Sandler Reiterates Overweight on Immunic, Maintains $28 Price Target

Immunic Says Jason Tardio Will Be Joining Company As COO And President, Effective July 12, 2024

Immunic Raises Size Of Mixed Shelf Offering From $250M To $412.3M

Recent Analyst Ratings for
$IMUX

$IMUX
SEC Filings

$IMUX
Insider Purchases

$IMUX
Large Ownership Changes

$IMUX
Leadership Updates

$IMUX
Insider Trading

$IMUX
Financials

$IMUX
Press Releases

$IMUX
Analyst Ratings

$IMUX
Market Insights